Filter Results:
(94)
Show Results For
- All HBS Web (94)
- Faculty Publications (25)
Show Results For
- All HBS Web (94)
- Faculty Publications (25)
- 01 Sep 2008
- News
Mara Aspinall
1,500-person division is a leader in the emerging field of personalized medicine, which treats cancer and other diseases with customized therapies that take into account the patient’s specific genetic traits. With HBS professor Richard... View Details
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
drugs, and will they be less expensive?' My answer is, 'I don't know, and probably not.' Lechleiter was one of several panelists to discuss, "Breaking the Genetic Code: The Business of Life Science in the 21st Century" at the... View Details
Keywords: by Sean Silverthorne
- 26 Sep 2024
- Blog Post
Syngenta Tomato Vision
years. However, only about 2% of all tested varieties in the greenhouse end up commercialized! Syngenta’s technology differs from genetically modified organisms (GMO) as they only leverage genes that exist... View Details
- 17 Nov 2003
- Research & Ideas
The Business of Babies
Chinese babies), and international restrictions and legislation concerning adoption. High-tech measures include IVF, artificial insemination, surrogacy, gamete interfallopian transfer (GIFT) in which the sperm is injected directly into the fallopian tube,... View Details
- 01 Mar 2017
- News
Alumni Take Cold Calls in New York City
focused on 23andMe, whose sale of genetic testing kits directly to consumers was challenged by the Food & Drug Administration. Quelch, who coauthored the case, is also on the faculty of the Harvard T.H. Chan... View Details
- 10 Dec 2010
- News
Notes from the Trenches
on his company’s board. Good Start, which closed an $18 million Series A round of fundraising in September, will use advanced DNA sequencing technology for a pre-pregnancy test to more accurately screen for a range of potential View Details
- 12 Nov 2015
- Research & Ideas
Can Consumers be Trusted with Their Own Health Care?
reveals a person’s genetically based health risk across dozens of disease categories. 23andMe test results showed one patient at higher risk of liver and bowel cancer—and that made sense, given family... View Details
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
- 01 Jun 2000
- News
The Business of Biotech
December). Amgen's Epogen (a treatment for anemia in kidney dialysis patients) and Neupogen (which restores white blood cells in cancer patients) generated more than $2 billion in sales last year. As the ability to analyze a patient's View Details
Keywords: Julia Hanna
- 01 Feb 1999
- News
Classmates Rally to Help Family Stricken with Rare Disease
a genetic enzyme deficiency that leads to rapid muscle deterioration and death from respiratory failure, usually before age five. Although fewer than one thousand children worldwide suffer from any form of Pompe's disease, the Crowleys'... View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
question—it’s clear.” Simply put, inefficiencies in the development of precision medicine can best be addressed by a business-analysis approach. With the mapping of the human genome completed 15 years ago, the sci-fi concept of using a cancer patient’s View Details
- 15 Apr 2014
- First Look
First Look: April 15
Pooled Income Funds. Purchase this case: http://hbr.org/product/choosing-a-charitable-giving-vehicle/an/314073-PDF-ENG Harvard Business School Case 514-086 23andMe: Genetic Testing for Consumers (A) On... View Details
Keywords: Sean Silverthorne
- 23 Nov 2010
- First Look
First Look: November 23
School Case 811-014 The Ze-gen case covers the first five years in the life of a clean-tech start-up. Ze-gen had developed an innovative technology that converted solid waste into synthesis gas (called syngas). This technology was in View Details
Keywords: Sean Silverthorne
- 11 Jun 2021
- News
The Power of Resilience
what my priorities are. I actually didn't know what that mission-driven work would be at the time. But I came across a company whose mission it was to democratize access to genetic testing for hereditary... View Details
- 06 Dec 2021
- News
Vision: Sound Science
genes to the inner ear with unprecedented efficiency.” The five-year-old company will likely apply for clinical testing permission for its lead therapy in the first half of 2022—a key hurdle in the notoriously lengthy process of advancing... View Details
Keywords: Deb Blagg
- 23 Jan 2019
- News
The Promise of Personalized Medicine
University of Cincinnati every year for treatment? Why does he seem to struggle to walk? Horgan eventually came to understand that his brother suffers from Duchenne muscular dystrophy—a fatal, childhood genetic disease that impacts about... View Details
- Web
Winners & Success Stories | New Venture Competition
Good Start Genetics is developing a low-cost, sequencing based, pre-pregnancy test for multiple genetic disorders that will replace one-disorder-only View Details
- 15 Dec 2015
- News
The Year in Ideas 2015
create informed, online test prep through Khan Academy. Free, accessible coaching, Khan reasons, will help “level the playing field”—giving every student, everywhere access to elite-level SAT coaching. J.R. Simplot’s White Russet is... View Details
- 01 Mar 2019
- News
The Blue-Green Revolution
the single-celled organisms to bulk up on fat like bears preparing for winter. Alas, just like bears, the microscopic butterballs eventually go into hibernation. And once that happens, they stop growing, negating the gains made in oil production. SGI solved that... View Details
- 14 Jul 2009
- First Look
First Look: July 14
Course MaterialsThe DiagnoFirst Opportunity Harvard Business School Case 309-112 John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a View Details
Keywords: Martha Lagace